Inotuzumab Ozogamicin in the Treatment of MRD+ After HSCT of ALL

As part of postremission consolidative therapy, the decision to proceed with hematopoietic stem cell transplantation is a recommendable regimen in ALL therapy. However, The recurrence rate is high after transplantation. Minimal Residual Disease (MRD) is an important factor affecting the effect of HSCT.

Comparison of Eligible TAVI-valves - Cohort B

The study performs head-to-head comparison of two TAVI-valves: Sapien and Myval.

None

None

None

None

None

None

None

None